Ambrx Biopharma Gross Margin 2020-2021 | AMAM

Current and historical gross margin for Ambrx Biopharma (AMAM) over the last 10 years. The current gross profit margin for Ambrx Biopharma as of June 30, 2021 is %.
Ambrx Biopharma Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.188B $0.014B
Ambrx Biopharma Inc. is a clinical stage biopharmaceutical company using an expanded genetic code technology platform to discover and develop Engineered Precision Biologics. Ambrx Biopharma Inc. is based in SAN DIEGO.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.747B 8.96
Bio-Rad Laboratories (BIO.B) United States $17.038B 34.58
QIAGEN (QGEN) Netherlands $10.791B 18.27
Biohaven Pharmaceutical Holding (BHVN) United States $7.896B 0.00
Emergent Biosolutions (EBS) United States $2.380B 8.56
Arcus Biosciences (RCUS) United States $2.057B 0.00
Myovant Sciences (MYOV) United Kingdom $1.157B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.011B 0.00
Zymeworks (ZYME) Canada $0.386B 0.00
SQZ Biotechnologies (SQZ) United States $0.178B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.88